Skip to main content
Fig. 3 | BMC Immunology

Fig. 3

From: CTLA4+CD4+CXCR5FOXP3+ T cells associate with unfavorable outcome in patients with chronic HBV infection

Fig. 3

HBV antigens induce the elevated inhibitory molecules of CD4+CXCR5FOXP3+ T cells. (A) The gating strategy for CXCR5FOXP3+ T cells in CD4+T cells of control, HBsAg, HBeAg, and HBcAg groups (left), and the frequency of circulating CD4+CXCR5FOXP3+ T cells between control and corresponding HBsAg (n = 15), HBeAg (n = 18), and HBcAg (n = 18) groups. (B) Histogram showing the frequencies of surface markers (CTLA4, PD-1, TIGIT, Tim3) in CD4+CXCR5FOXP3+ T cells with different rHBV Ag or control stimulation. (C) Comparison of the frequencies of intracellular molecules (TGF-β, IL-10, and Granzyme B) in CD4+CXCR5FOXP3+ T cells in the three paired groups, respectively. Wilcoxon signed-rank test. *p < 0.05, **p < 0.01, ***p < 0.001. rHBV Ag, recombination HBV antigen

Back to article page